Sociedad Americana de Hirudoterapia

Essential Hypertension (Adjunctive)

Investigational adjunctive use; mechanism includes mild diuresis from blood-volume removal and hirudin-mediated vascular endothelial effects. Not a substitute for pharmacotherapy.

Tier C — InvestigationalInvestigacionalLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Resumen para el Paciente

¿Está esto autorizado por FDA para este uso?
Not FDA-cleared for hypertension. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for high blood pressure is investigational.
¿Qué evidencia existe?
Tier C (investigational). Small case series suggest modest, short-term systolic blood pressure reductions (about 8 to 12 mmHg) after 2 to 3 sessions, with no controlled trials and no long-term outcome data on heart attack or stroke. Evidence-based first-line therapy is lifestyle change (sodium reduction, weight loss, exercise, alcohol moderation) plus proven antihypertensive medications (thiazides, ACE inhibitors / ARBs, calcium channel blockers) — these have decades of cardiovascular-outcome data behind them.
Riesgos principales
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Bruising and tenderness over the placement areas for 5 to 10 days
  • Lightheadedness or low blood pressure on standing, especially if antihypertensive medications are not adjusted
  • Local skin infection or, rarely, Aeromonas infection
  • Allergic reaction to leech saliva (uncommon)
  • Anemia from cumulative blood loss across multiple sessions
  • False reassurance leading to skipping or delaying evidence-based pharmacotherapy — with risk of heart attack, stroke, kidney disease
Quién no debería considerar esto
  • Patients with severe uncontrolled hypertension (BP over 180/110)
  • Patients within 6 months of a heart attack, stroke, or transient ischemic attack
  • Patients with symptomatic orthostatic hypotension or frequent falls
  • Patients on anticoagulants (warfarin INR over 2.0, DOACs, heparin)
  • Patients with hemophilia, severe anemia (Hb under 10 g/dL), or active infection
  • Patients using this as a replacement for prescribed antihypertensives
Qué preguntar a su clínico
  • What is my cardiovascular risk score, and what is my blood-pressure target?
  • Have I tried lifestyle modification (DASH diet, sodium under 1500 mg/day, regular aerobic exercise, weight loss if applicable)?
  • What antihypertensive medications have I tried, and at what doses?
  • Will my prescriber be involved in dose adjustment if I pursue complementary therapy?
  • How will my blood pressure be monitored during and after treatment (home BP log)?
  • What is the practitioner's experience and Aeromonas-prevention plan?
  • What is the realistic effect size and duration?
Cuándo buscar atención urgente
  • Chest pain, pressure, or shortness of breath (possible heart attack — call 911)
  • Sudden weakness on one side, slurred speech, facial droop, or vision loss (possible stroke — call 911)
  • Blood pressure over 180/120 with headache, vision change, or chest pain (hypertensive emergency)
  • Severe lightheadedness, fainting, or a fall
  • Bleeding from a bite site lasting more than 24 to 48 hours
  • Fever above 38.0 C / 100.4 F, spreading redness, or pus
  • Hives, throat tightness, or breathing difficulty

Qué NO significa esto

  • This is not FDA-cleared for hypertension.
  • Small short-term BP reductions in case series do NOT prove reduction of heart attack, stroke, or kidney damage.
  • Mechanism rationale (volume reduction, endothelial effects) does NOT establish clinical efficacy at scale.
  • Leech therapy is NEVER a substitute for evidence-based antihypertensive medications when indicated.
  • Any antihypertensive medication changes require your prescriber's involvement, not self-titration.

Clinical Profile

Category
cardiovascular
ICD-10
I10
Safety tier
medium

Evidence Summary

Historical use of bloodletting for hypertension dates to antiquity. No controlled clinical trial or case series of leech therapy for essential or resistant hypertension has been published; human clinical evidence is absent and any use is investigational and mechanistic only. The proposed mechanism combines a temporary blood-volume reduction (analogous to therapeutic phlebotomy in polycythemia) with hypothesized endothelial effects from absorbed salivary peptides, but neither has been demonstrated to lower blood pressure in patients. ASH position: leech therapy is NEVER a replacement for evidence-based antihypertensive pharmacotherapy and should not be used as a substitute for it. It has no established role in the management of hypertension and should only be considered, if at all, within a research protocol under cardiology supervision.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Ashraf S et al. (2014), n=44
  2. Khalil M et al. (2019), n=22
Sample sizes of key trials for Essential Hypertension (Adjunctive)Ashraf S et al. 201444Khalil M et al. 201922
Participants per key trial (n). Larger trials generally carry more statistical weight; case series with unspecified counts are omitted.

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Uncontrolled severe hypertension (BP >180/110)
  • Recent (<6 months) myocardial infarction or stroke
  • Symptomatic orthostatic hypotension

Related ASH Compounds

Leech-derived molecules implicated in this condition, each profiled in the ASH compound registry:

Related Conditions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.

Essential Hypertension (Adjunctive) — Hirudotherapy Evidence | ASH